MBX Biosciences Inc Financials
This page shows MBX Biosciences Inc (MBX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
MBX’s current model is cash-funded drug development, with research spending driving losses while repeated financings rebuild the balance sheet.
From FY2023 to FY2025, R&D spending climbed from$28.5M to$79.2M while free cash burn moved from-$32.1M to-$81.9M ; because capex stayed just$129K to$1.9M , the extra cash use is coming from program expansion rather than building a capital-heavy operating base. Financing inflows of$234.1M in FY2024 and$189.6M in FY2025 are what turned FY2023’s-$72.5M equity into$369.2M by FY2025, so the balance-sheet strength is externally supplied rather than internally earned.
In FY2025, net loss was
With cash of
Financial Health Signals
Based on FY2026 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of MBX Biosciences Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
MBX Biosciences Inc carries a low D/E ratio of 0.04, meaning only $0.04 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 24.62, MBX Biosciences Inc holds $24.62 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
MBX Biosciences Inc generates a -23.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -24.1% the prior year.
MBX Biosciences Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, MBX Biosciences Inc generates $0.92 in operating cash flow (-$79.9M OCF vs -$87.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
MBX Biosciences Inc's EBITDA was -$97.8M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 43.9% from the prior year.
MBX Biosciences Inc reported -$87.0M in net income in fiscal year 2026. This represents a decrease of 40.5% from the prior year.
MBX Biosciences Inc earned $-2.38 per diluted share (EPS) in fiscal year 2026. This represents an increase of 59.1% from the prior year.
Cash & Balance Sheet
MBX Biosciences Inc generated -$81.9M in free cash flow in fiscal year 2026, representing cash available after capex. This represents a decrease of 47.4% from the prior year.
MBX Biosciences Inc held $75.3M in cash against $0 in long-term debt as of fiscal year 2026.
MBX Biosciences Inc had 45M shares outstanding in fiscal year 2026. This represents an increase of 34.4% from the prior year.
Margins & Returns
MBX Biosciences Inc's ROE was -23.6% in fiscal year 2026, measuring profit generated per dollar of shareholder equity. This is up 0.5 percentage points from the prior year.
Capital Allocation
MBX Biosciences Inc invested $79.2M in research and development in fiscal year 2026. This represents an increase of 37.9% from the prior year.
MBX Biosciences Inc invested $1.9M in capex in fiscal year 2026, funding long-term assets and infrastructure. This represents an increase of 120.7% from the prior year.
MBX Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $18.5M | N/A | $19.3M+8.7% | $17.7M-20.9% | $22.4M | N/A | $16.7M+16.3% | $14.4M |
| SG&A Expenses | $8.8M | N/A | $4.7M+14.1% | $4.1M-1.0% | $4.1M | N/A | $2.9M+26.7% | $2.3M |
| Operating Income | -$27.3M | N/A | -$23.9M-9.7% | -$21.8M+17.8% | -$26.5M | N/A | -$19.6M-17.7% | -$16.7M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$23.5M | N/A | -$21.6M-11.4% | -$19.4M+18.7% | -$23.9M | N/A | -$18.1M-14.4% | -$15.9M |
| EPS (Diluted) | $-0.50 | N/A | $-0.63-8.6% | $-0.58+18.3% | $-0.71 | N/A | $-2.78+78.0% | $-12.62 |
MBX Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $452.7M+17.5% | $385.1M-3.7% | $400.1M+72.8% | $231.5M-5.9% | $245.9M-8.4% | $268.5M-4.9% | $282.4M | N/A |
| Current Assets | $448.5M+17.6% | $381.5M-4.0% | $397.5M+73.4% | $229.2M-6.2% | $244.3M-8.6% | $267.3M-4.9% | $281.2M | N/A |
| Cash & Equivalents | $45.2M-39.9% | $75.3M-66.3% | $223.1M+460.9% | $39.8M+33.0% | $29.9M-39.4% | $49.4M-62.9% | $132.9M | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $14.9M-6.1% | $15.9M+27.0% | $12.5M+2.1% | $12.3M+16.9% | $10.5M-5.3% | $11.1M+0.6% | $11.0M | N/A |
| Current Liabilities | $14.6M-6.0% | $15.5M+28.5% | $12.1M+2.6% | $11.8M+12.2% | $10.5M-5.2% | $11.1M+1.2% | $10.9M | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $437.8M+18.6% | $369.2M-4.7% | $387.5M+76.8% | $219.2M-6.9% | $235.4M-8.6% | $257.4M-5.1% | $271.4M+377.2% | -$97.9M |
| Retained Earnings | -$248.0M-10.5% | -$224.5M-10.9% | -$202.4M-12.0% | -$180.8M-12.0% | -$161.4M-17.4% | -$137.5M-12.8% | -$121.9M | N/A |
MBX Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$20.2M-10.4% | -$18.3M+15.0% | -$21.5M-23.5% | -$17.4M+23.1% | -$22.7M-41.4% | -$16.0M-9.4% | -$14.7M-10.5% | -$13.3M |
| Capital Expenditures | $437K-44.9% | $793K+98.7% | $399K-43.6% | $707K+2256.7% | $30K-67.4% | $92K+61.4% | $57K-87.4% | $452K |
| Free Cash Flow | -$20.6M-8.1% | -$19.1M+13.0% | -$21.9M-20.9% | -$18.1M+20.1% | -$22.7M-40.8% | -$16.1M-9.6% | -$14.7M-7.3% | -$13.7M |
| Investing Cash Flow | -$97.1M+25.3% | -$130.0M-862.0% | $17.1M-34.4% | $26.0M+705.5% | $3.2M+104.8% | -$67.3M+33.2% | -$100.8M-1177.3% | -$7.9M |
| Financing Cash Flow | $87.4M+19862.3% | $438K-99.8% | $187.8M+14064.7% | $1.3M+33050.0% | $4K+103.0% | -$132K-100.1% | $235.8M+13490.9% | -$1.8M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
MBX Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -5.4% | N/A | -5.6%+3.3pp | -8.8%+1.3pp | -10.1% | N/A | -6.7% | N/A |
| Return on Assets | -5.2% | N/A | -5.4%+3.0pp | -8.4%+1.3pp | -9.7% | N/A | -6.4% | N/A |
| Current Ratio | 30.79+6.2 | 24.62-8.3 | 32.95+13.5 | 19.50-3.8 | 23.31-0.9 | 24.19-1.6 | 25.75 | N/A |
| Debt-to-Equity | 0.030.0 | 0.04+0.0 | 0.03-0.0 | 0.06+0.0 | 0.040.0 | 0.040.0 | 0.04 | N/A |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is MBX Biosciences Inc profitable?
No, MBX Biosciences Inc (MBX) reported a net income of -$87.0M in fiscal year 2026.
What is MBX Biosciences Inc's EBITDA?
MBX Biosciences Inc (MBX) had EBITDA of -$97.8M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
What is MBX Biosciences Inc's return on equity (ROE)?
MBX Biosciences Inc (MBX) has a return on equity of -23.6% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is MBX Biosciences Inc's free cash flow?
MBX Biosciences Inc (MBX) generated -$81.9M in free cash flow during fiscal year 2026. This represents a -47.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is MBX Biosciences Inc's operating cash flow?
MBX Biosciences Inc (MBX) generated -$79.9M in operating cash flow during fiscal year 2026, representing cash generated from core business activities.
What are MBX Biosciences Inc's total assets?
MBX Biosciences Inc (MBX) had $385.1M in total assets as of fiscal year 2026, including both current and long-term assets.
What are MBX Biosciences Inc's capital expenditures?
MBX Biosciences Inc (MBX) invested $1.9M in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.
How much does MBX Biosciences Inc spend on research and development?
MBX Biosciences Inc (MBX) invested $79.2M in research and development during fiscal year 2026.
What is MBX Biosciences Inc's current ratio?
MBX Biosciences Inc (MBX) had a current ratio of 24.62 as of fiscal year 2026, which is generally considered healthy.
What is MBX Biosciences Inc's debt-to-equity ratio?
MBX Biosciences Inc (MBX) had a debt-to-equity ratio of 0.04 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is MBX Biosciences Inc's return on assets (ROA)?
MBX Biosciences Inc (MBX) had a return on assets of -22.6% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is MBX Biosciences Inc's cash runway?
Based on fiscal year 2026 data, MBX Biosciences Inc (MBX) had $75.3M in cash against an annual operating cash burn of $79.9M. This gives an estimated cash runway of approximately 11 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is MBX Biosciences Inc's Piotroski F-Score?
MBX Biosciences Inc (MBX) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are MBX Biosciences Inc's earnings high quality?
MBX Biosciences Inc (MBX) has an earnings quality ratio of 0.92x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is MBX Biosciences Inc?
MBX Biosciences Inc (MBX) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.